|Videos|July 24, 2023
Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC
Author(s)Joshua K. Sabari, MD, Misako Nagasaka, MD
Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.
Advertisement
Episodes in this series
Advertisement
Related to this article
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Chinmay Jani, MD, highlights nonsmoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
European Commission Expands Melflufen Label to Third-Line Multiple Myeloma
5